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Background & objectives: The effect of aqueous extract of Tinospora cordifolia, an immunomodula-
tor with  antimalarial activity along with chloroquine was studied  in the treatment of three cases of
hyper-reactive malarious splenomegaly in District Hospital, Daltonganj town, Jharkhand, India. These
cases were partial/slow responders to the conventional antimalarial drug chloroquine.
Methods: Aqueous extract of T. cordifolia (500 mg) was added to chloroquine (CQ) base (300 mg)
weekly and CQ prophylaxis  was observed up to six months.  Improvement was gauzed by measuring
spleen enlargement, Hb, serum IgM and well-being in three cases of hyper-reactive malarious sple-
nomegaly.
Results: Addition of extract of  T. cordifolia for the first six weeks to chloroquine showed regression
of spleen by  37–50% after six weeks and 45–69% after six months from the start of treatment. Likewise
decrease in IgM and increase in Hb as well as wellbeing (Karnofsky performance scale) were ob-
served.
Conclusion: The results of the present study paves a new sight in the treatment of hyper-reactive
malarious splenomegaly, however, large-scale trial is required to confirm the beneficial effect of T.
cordifolia extract in combination with chloroquine.
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Tinospora cordifolia, a climbing shrub belonging to
the family Menispermaceae is widely distributed
throughout Indian subcontinent and China1. Aqueous
extract of stem and root of the plant has been used
therapeutically because of immunomodulation proper-
ty as well as antimalarial and antileprotic activities1,2.
The aqueous extract contains a number of chemical
constituents—alkaloids, steroids, glycosides, polysac-
charides, etc. The practice in Ayurveda—Indian Sys-
tem of Medicine is to prescribe decoction of stem of
Tinospora with piper longam in malarial fever. It helps
in reducing splenomegaly too. The alcoholic extract of
the plant is prescribed in Ayurveda and Allopathy as
an immune promotor. Hyper-reactive malarious sple-
nomegaly (HMS) is thought to be the result of immu-
nological dysfunction due to recurrent episodes of ma-
laria. HMS is treated by chloroquine (CQ)/proguanil/
pyrimethamine prophylaxis3. There is paucity of clini-
cal trials to compare the efficacy of different antima-
larial drugs in HMS. Duration of treatment in HMS is
also not clear. Some view for lifelong prophylaxis,
while others favour for more than a year. However,
immunological abnormalities in tropical splenomega-
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bodies against Plasmodium vivax and low circulating
T-lymphocytes reverted towards normal after 9–26
months of weekly CQ prophylaxis4. Cases of fulmi-
nant HMS have been uncommonly reported and were
treated with steroids and cytotoxic drugs5.
Reports of three cases of HMS having defined crite-
ria6 (spleen size > 10 cm, IgM > 2 SD of local mean
and response to antimalarial treatment) are presented.
The ethical clearance was obtained from the Ethic
Committee of District Hospital, Daltonganj. All three
patients gave their free consent for the present study.
All the three cases (case 1—45 yr male, case 2—25
yr female and case 3—50 yr male) were partial/slow
respondent cases of HMS (spleen shrinkage rate was
15–20%) to CQ (Resochin, Bayer’s India) 300 mg
base weekly prophylaxis given for one year. All the
three cases belonged to Daltonganj town (India) being
endemic zone for vivax malaria. After dropping CQ
for 2–3 months they developed fever (100–104oC)
and haemolytic anaemia during April to June 2003.
Clinical examination revealed no other observable
cause of huge splenomegaly.  Total and differential
WBC counts were within normal range except low
haemoglobin level. Malarial parasites were not found
in peripheral blood smear, however, high titres of ma-
larial antibodies against P. vivax were present. Raised
serum bilirubin (mostly unconjugated) was estimated
and direct coombs test was found negative. Urinalysis
showed presence of haemoglobin. Deficiency of Glu-
cose 6-phosphate dehydrogenase was not demon-
strated. Liver function tests were normal with absence
of viral markers. Aqueous extract of Tinospora cordi-
folia (Immumod, Wockhardt Ltd., India) 500 mg
(tablet) bd daily for six weeks was added to CQ 300
mg base weekly. CQ prophylaxis was continued for
six months. Improvement was gauzed by measuring
spleen enlargement, Hb, serum IgM and wellbeing
(Karnofsky performance scale7) at Day 0, 6 weeks
and 6 months (Day 0 being the first day of Immumod
administration) (Table 1). Fundus examination was
done prior and after CQ administration. Immumod
was found to be safe drug as it produced no side ef-
fects in these cases.
In case 1 spleen regression was found 50% at six
weeks and 67% at six months, while case 2 had
spleen regression by 50% after six weeks and 45%
after 6 months. Case 3 had spleen regression 37 and
69% after six weeks and 6 months respectively. In-
crement of Hb, reduction in serum IgM and well-be-
ing were marked as shown in Table 1.
Three cases of HMS who were given one year CQ
prophylaxis showed slow rather partial response on
the basis of reduction in spleen size. Response of anti-
malarial drug in HMS has been termed as good re-
sponse or partial/slow response if spleen shrinkage is
>40% or between 15 and 30% respectively.  These
cases developed haemolytic episode with fever at one
stage after dropping CQ prophylaxis. Episodes of
haemolysis occur occasionally in HMS and appear to
Table 1.  Showing clinical and biochemical profile of the cases
Parameters Case 1 Case 2 Case 3
   studied
Day 0 6 wk 6 mth Day 0 6 wk 6 mth Day 0 6 wk 6 mth
Spleen size (cm) 12 6 4 10 5 4.5 16 12 4
Hb (g/dl) 10 12 13.6 8 9.6 10.2 4.8 6.5 10.5
IgM (mg/dl) 400 310 280 295 180 180 1755 750 300
Well-being (%) 70 90 90 80 90 90 60 80 90
Bilirubin (mg/dl) 2.4 0.6 0.8 2.3 0.8 0.8 1.8 1 0.6J  VECT  BORNE  DIS  42, MARCH  2005 38
be due to autoimmune, cold agglutinin mediated re-
sponse triggered by non-patent parasitaemia9. Addi-
tion of T. cordifolia aqueous extract to the treatment
of HMS for initial six weeks accelerated the well-be-
ing with subsidence of haemolytic state besides
marked reduction in spleen size and serum IgM as
well as rise in Hb in all the three cases. Its beneficial
effect in HMS was perhaps shown due to its immu-
modulatory effect as well as additive effect on antima-
larial activity of CQ. This report, on a small number of
cases, paves new insight in the treatment of HMS.
However, trial on large number of cases is required to
confirm its beneficial effect.
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